Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3) > Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3):227-38

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014


eTOC

 

REVIEWS  


Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3):227-38

language: English

What’s new in antibiotics in the management of acne?

Narahari S. 1, Gustafson C. J. 1, Feldman S. R. 1, 2, 3

1 Center for Dermatology Research, Wake Forest University, Baptist Medical Center, Winston-Salem, NC, USA;
2 Department of Dermatology, Wake Forest University, Baptist Medical Center, Winston-Salem,NC, USA;
3 Department of Pathology, Wake Forest University, Baptist Medical Center, Winston-Salem, NC, USA


PDF  


Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit with a multifactorial pathogenesis. Topical and oral antibiotics are a mainstay treatment for inflammatory acne lesions and are widely utilized for all levels of disease severity. Over the past forty years, a gradual increase in antibacterial-resistant strains of Propionibacterium acnes has changed the way practitioners use antibiotics to manage acne. Updated recommendations call for avoiding antibiotic monotherapy and prescribing it in combination with benzoyl peroxide or retinoids. In addition to reducing the risk of developing bacterial resistance, antibiotics prescribed in combination formulations with benzoyl peroxide or retinoids are more efficacious than monotherapy, provide fast therapeutic results, and are associated with greater patient adherence due to the simplification of treatment regimens. Newer management strategies include limiting antibiotic use to the initial 3-6 months of treatment and then switching to topical retinoids for maintenance therapy.

top of page

Publication History

Cite this article as

Corresponding author e-mail

cgustafs@wakehealth.edu